Merrill Upgrades Lilly to Buy

Analyst David Risinger cites the drug maker's underappreciated pipeline

Merrill Lynch upgraded Eli Lilly (LLY ) to buy from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.